Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
KROS on Nasdaq
Shares outstanding
30,284,111
Price per share
$20.36
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
35,272,183
Total reported value
$558,013,727
% of total 13F portfolios
0%
Share change
-672,146
Value change
-$7,638,925
Number of holders
150
Price from insider filings
$20.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Madison Avenue Partners, LP 6.4% $37,150,652 2,614,402 Madison Avenue Partners, LP 07 May 2025
VANGUARD GROUP INC 6.3% $36,467,421 2,566,321 The Vanguard Group 31 Mar 2025
TANG CAPITAL MANAGEMENT LLC 7.9% $38,268,569 2,418,984 TANG CAPITAL MANAGEMENT, LLC 15 Oct 2025
ExodusPoint Capital Management, LP 6.3% $28,675,722 1,907,899 ExodusPoint Capital Management, LP 10 Nov 2025
D. E. SHAW & CO, L.P. 5.1% $24,457,052 1,545,948 D. E. Shaw & Co., L.P. 20 Oct 2025
ALKEON CAPITAL MANAGEMENT LLC 2.7% $15,645,210 1,101,000 Alkeon Capital Management LLC 31 Dec 2024
FMR LLC 1.7% $10,010,547 704,472 FMR LLC 31 Jan 2025
JPMORGAN CHASE & CO 0.2% -102% $1,617,141 -$35,146,204 113,803 -96% JPMORGAN CHASE & CO. 30 Apr 2025

As of 30 Sep 2025, 150 institutional investors reported holding 35,272,183 shares of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS). This represents 116% of the company’s total 30,284,111 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) together control 99% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ADAR1 Capital Management, LLC 18% 5,389,264 0% 8.5% $85,258,156
VANGUARD GROUP INC 9% 2,718,777 +3.3% 0% $43,011,052
BlackRock, Inc. 9% 2,717,153 -0.57% 0% $42,985,352
Madison Avenue Partners, LP 8.9% 2,708,218 +0.62% 2.6% $42,844,009
Western Standard LLC 7.2% 2,189,882 +43% 19% $34,643,933
TANG CAPITAL MANAGEMENT LLC 4.7% 1,418,984 0% 0.86% $22,448,327
D. E. Shaw & Co., Inc. 4.4% 1,331,425 +2.6% 0.02% $21,063,144
GOLDMAN SACHS GROUP INC 4.4% 1,325,483 +50% 0% $20,969,141
STATE STREET CORP 4.3% 1,302,978 -5.9% 0% $20,613,112
Nantahala Capital Management, LLC 4.1% 1,233,189 -24% 1.2% $19,509,050
ORBIMED ADVISORS LLC 3.4% 1,018,734 0% 0.39% $16,116,372
ALKEON CAPITAL MANAGEMENT LLC 2.8% 850,511 0% 0.06% $13,455,084
Logos Global Management LP 2.8% 850,000 -58% 1.3% $13,447,000
GEODE CAPITAL MANAGEMENT, LLC 2.8% 837,363 +0.97% 0% $13,249,727
JACOBS LEVY EQUITY MANAGEMENT, INC 2% 607,089 +16% 0.04% $9,604,148
Redmile Group, LLC 1.8% 552,506 0% 0.85% $8,740,645
FEDERATED HERMES, INC. 1.7% 514,160 -21% 0.01% $8,134,011
MORGAN STANLEY 1.3% 395,103 -55% 0% $6,250,537
Connor, Clark & Lunn Investment Management Ltd. 1.1% 335,154 +26% 0.02% $5,302,136
PDT Partners, LLC 1.1% 332,815 0% 0.33% $5,265,133
NORTHERN TRUST CORP 1.1% 332,758 +22% 0% $5,264,231
Qube Research & Technologies Ltd 1% 303,122 +684% 0.01% $4,795,390
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 292,006 +3% 0% $4,619,535
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.85% 258,754 +301% 0% $4,093,488
Rangeley Capital, LLC 0.85% 258,619 -9.4% 3.9% $4,091,353

Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 147,482 $3,003,141 -$1,626,477 $20.36 8
2025 Q3 35,272,183 $558,013,727 -$7,638,925 $15.82 150
2025 Q2 35,922,272 $479,567,957 +$53,894,426 $13.35 134
2025 Q1 32,796,190 $334,208,916 -$101,548,195 $10.19 154
2024 Q4 36,741,918 $581,640,265 -$99,583,348 $15.83 159
2024 Q3 34,948,467 $2,029,993,469 +$197,656,348 $58.07 162
2024 Q2 31,483,081 $1,437,735,495 -$1,704,535 $45.70 150
2024 Q1 31,378,208 $2,077,197,760 +$376,189,592 $66.20 144
2023 Q4 25,748,679 $1,023,986,857 +$107,389,201 $39.76 119
2023 Q3 22,915,590 $730,562,303 +$10,983,703 $31.88 106
2023 Q2 22,423,232 $900,980,099 +$13,493,306 $40.18 121
2023 Q1 22,003,238 $936,983,921 +$94,494,039 $42.70 128
2022 Q4 19,814,952 $951,517,038 +$88,887,412 $48.02 122
2022 Q3 18,166,429 $683,394,048 +$33,259,877 $37.62 107
2022 Q2 17,360,328 $479,673,115 +$10,253,619 $27.63 101
2022 Q1 16,425,972 $892,979,574 +$13,785,386 $54.38 101
2021 Q4 16,155,340 $944,400,680 +$68,408,989 $58.51 96
2021 Q3 13,732,777 $543,300,250 -$15,835,150 $39.56 86
2021 Q2 14,120,390 $599,680,759 -$43,588,395 $42.47 79
2021 Q1 14,412,080 $887,014,019 -$122,639,102 $61.55 83
2020 Q4 16,029,747 $1,129,296,879 +$301,336,670 $70.54 81
2020 Q3 11,780,724 $454,579,430 +$33,779,230 $38.57 49
2020 Q2 10,926,163 $409,790,602 +$409,790,602 $37.51 51